openPR Logo
Press release

Lateral Epicondylitis (Tennis Elbow) Disease Market Forecasted to Surge in Coming Years, 2023-2032 Analysis by DelveInsight | Cell Therapy Ltd., BioMimetic Therapeutics, Travanti Pharma Inc, Causeway Therapeutics, AlgoRx Pharmaceutical, Anterogen Co.

04-28-2025 09:08 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Lateral Epicondylitis (Tennis Elbow) Disease Market

DelveInsight's "Lateral Epicondylitis Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Lateral Epicondylitis, historical and forecasted epidemiology as well as the Lateral Epicondylitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Lateral Epicondylitis, offering comprehensive insights into the Lateral Epicondylitis revenue trends, prevalence, and treatment landscape. The report delves into key Lateral Epicondylitis statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Lateral Epicondylitis therapies. Additionally, we cover the landscape of Lateral Epicondylitis clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Lateral Epicondylitis treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Lateral Epicondylitis space.

To Know in detail about the Lateral Epicondylitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Lateral Epicondylitis Market Forecast
https://www.delveinsight.com/sample-request/lateral-epicondylitis-tennis-elbow-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Lateral Epicondylitis Market Report:
• The Lateral Epicondylitis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• Key Lateral Epicondylitis Companies: Cell Therapy Ltd., BioMimetic Therapeutics, Travanti Pharma Inc, Causeway Therapeutics, AlgoRx Pharmaceutical, Anterogen Co., Ltd., and others
• Key Lateral Epicondylitis Therapies: Tendoncel, rhPDGF-BB Injection, Dexamethasone Iontophoretic Patch, TenoMiR, ALGRX 49, a75, ALLO-ASC-TI, and others
• The Lateral Epicondylitis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Lateral Epicondylitis pipeline products will significantly revolutionize the Lateral Epicondylitis market dynamics.
• The Prevalence of Lateral Epicondylitis Epidemiological Affects about 1-3% of the general population annually.
• Most commonly seen in people between 30 to 50 years of age.
• Affects both genders equally, though some studies show a slight male predominance
• Higher incidence among manual laborers, athletes, and workers involved in repetitive arm movements
• Typically affects the dominant arm (right-handed or left-handed).
• About 5-10% of cases may become chronic, requiring prolonged treatment

Lateral Epicondylitis Overview
Lateral Epicondylitis, commonly known as Tennis Elbow, is a condition caused by overuse of the forearm muscles, leading to pain and tenderness around the outer part of the elbow. It often develops from repetitive motions like gripping, lifting, or racquet sports. Symptoms include pain, weakness, and difficulty in hand or wrist movements. Treatment usually involves rest, physical therapy, medications, or, in severe cases, surgery.

Get a Free sample for the Lateral Epicondylitis Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/lateral-epicondylitis-tennis-elbow-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Lateral Epicondylitis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Lateral Epicondylitis Epidemiology Segmentation:
The Lateral Epicondylitis market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Lateral Epicondylitis
• Prevalent Cases of Lateral Epicondylitis by severity
• Gender-specific Prevalence of Lateral Epicondylitis
• Diagnosed Cases of Episodic and Chronic Lateral Epicondylitis

Download the report to understand which factors are driving Lateral Epicondylitis epidemiology trends @ Lateral Epicondylitis Epidemiology Forecast
https://www.delveinsight.com/sample-request/lateral-epicondylitis-tennis-elbow-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Lateral Epicondylitis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Lateral Epicondylitis market or expected to get launched during the study period. The analysis covers Lateral Epicondylitis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Lateral Epicondylitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Lateral Epicondylitis Therapies and Key Companies
• Tendoncel: Cell Therapy Ltd.
• rhPDGF-BB Injection: BioMimetic Therapeutics
• Dexamethasone Iontophoretic Patch: Travanti Pharma Inc
• TenoMiR: Causeway Therapeutics
• ALGRX 4975: AlgoRx Pharmaceutical
• ALLO-ASC-TI: Anterogen Co., Ltd.

Discover more about therapies set to grab major Lateral Epicondylitis market share @ Lateral Epicondylitis Treatment Landscape
https://www.delveinsight.com/sample-request/lateral-epicondylitis-tennis-elbow-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Lateral Epicondylitis Market Drivers
• Rising incidence of sports injuries and repetitive strain injuries.
• Increasing awareness about musculoskeletal disorders and early diagnosis.
• Advancements in non-surgical treatments like biologics (PRP therapy, stem cells).
• Growing demand for minimally invasive procedures and effective therapies.
• Expansion of rehabilitation services and physical therapy options.
• R&D initiatives focusing on innovative pain management solutions.

Lateral Epicondylitis Market Barriers
• High cost of advanced biologic therapies and surgical procedures.
• Limited efficacy of current non-invasive treatments for chronic cases.
• Delayed diagnosis due to symptom overlap with other elbow disorders.
• Low patient compliance with long-term physical therapy programs.
• Side effects and complications associated with steroid injections and surgeries. Side effects and complications associated with steroid injections and surgeries

Scope of the Lateral Epicondylitis Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Lateral Epicondylitis Companies: , Cell Therapy Ltd., BioMimetic Therapeutics, Travanti Pharma Inc, Causeway Therapeutics, AlgoRx Pharmaceutical, Anterogen Co., Ltd. and others
• Key Lateral Epicondylitis Therapies: Tendoncel, rhPDGF-BB Injection, Dexamethasone Iontophoretic Patch, TenoMiR, ALGRX 4975, ALLO-ASC-TI, and others
• Lateral Epicondylitis Therapeutic Assessment: Lateral Epicondylitis current marketed and Lateral Epicondylitis emerging therapies
• Lateral Epicondylitis Market Dynamics: Lateral Epicondylitis market drivers and Lateral Epicondylitis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Lateral Epicondylitis Unmet Needs, KOL's views, Analyst's views, Lateral Epicondylitis Market Access and Reimbursement

To know more about Lateral Epicondylitis companies working in the treatment market, visit @ Lateral Epicondylitis Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/lateral-epicondylitis-tennis-elbow-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Lateral Epicondylitis Market Report Introduction
2. Executive Summary for Lateral Epicondylitis
3. SWOT analysis of Lateral Epicondylitis
4. Lateral Epicondylitis Patient Share (%) Overview at a Glance
5. Lateral Epicondylitis Market Overview at a Glance
6. Lateral Epicondylitis Disease Background and Overview
7. Lateral Epicondylitis Epidemiology and Patient Population
8. Country-Specific Patient Population of Lateral Epicondylitis
9. Lateral Epicondylitis Current Treatment and Medical Practices
10. Lateral Epicondylitis Unmet Needs
11. Lateral Epicondylitis Emerging Therapies
12. Lateral Epicondylitis Market Outlook
13. Country-Wise Lateral Epicondylitis Market Analysis (2019-2032)
14. Lateral Epicondylitis Market Access and Reimbursement of Therapies
15. Lateral Epicondylitis Market Drivers
16. Lateral Epicondylitis Market Barriers
17. Lateral Epicondylitis Appendix
18. Lateral Epicondylitis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Latest Reports by DelveInsight
Inflammatory Bowel Disease Market: https://www.delveinsight.com/report-store/crohns-disease-cd-market
• Post Menopausal Osteoporosis Market: https://www.delveinsight.com/report-store/post-menopausal-osteoporosis-pipeline-insight
• HiPost Menopausal Osteoporosis Market: https://www.delveinsight.com/report-store/post-menopausal-osteoporosis-pipeline-insight
• Hip Replacement Devices Market: https://www.delveinsight.com/report-store/hip-reconstruction-devices-market
• Amblyopia Market: https://www.delveinsight.com/report-store/amblyopia-market
• Type 2 Diabetes Market: https://www.delveinsight.com/report-store/diabetes-market
• Parp Poly Adp-ribose Polymerase Inhibitor Market: https://www.delveinsight.com/report-store/poly-adp-ribose-polymerase-1-parp-inhibitor-pipeline-insight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Lateral Epicondylitis (Tennis Elbow) Disease Market Forecasted to Surge in Coming Years, 2023-2032 Analysis by DelveInsight | Cell Therapy Ltd., BioMimetic Therapeutics, Travanti Pharma Inc, Causeway Therapeutics, AlgoRx Pharmaceutical, Anterogen Co. here

News-ID: 3991367 • Views:

More Releases from DelveInsight Business Research

Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibrillation Space by DelveInsight
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals. Objective of the Case Study The
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestones, Therapies in Development, Mechanisms of Action, and Routes of Administration - By DelveInsight
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics. According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Rising Cancer Burden and Technological Advancements, states DelveInsight
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies. Biopsy devices play a crucial role in disease diagnosis by
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven by Rising Surgical Procedures, Technological Advancements, and Growing Adoption of Minimally Invasive Techniques, States DelveInsight
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide. DelveInsight's General Surgery Devices Market Report 2032 provides

All 5 Releases


More Releases for Lateral

Emerging Trends Influencing The Growth Of The Lateral Flow Assays Market: Techno …
The Lateral Flow Assays Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Projected Growth of the Lateral Flow Assays Market? The market for lateral flow assays has seen significant expansion in the previous years. This market is projected to increase from $11.69 billion
Lateral Flow Strip Cutter
In the fast-evolving world of diagnostics and medical testing, lateral flow assays (LFAs) have become a game-changer. But behind every efficient LFA lies a critical piece of equipment-the lateral flow strip cutter. Without accurate cutting of these delicate strips, even the best-designed test can fail. Today, we're diving deep into the world of lateral flow strip cutters, understanding their role, features, types, and how they keep the gears of diagnostic
Amyotrophic Lateral Sclerosis Pipeline Therapeuetics Report 2024
DelveInsight's, "Amyotrophic Lateral Sclerosis Pipeline Insight 2024" report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Amyotrophic Lateral Sclerosis pipeline landscape. It covers the Amyotrophic Lateral Sclerosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Amyotrophic Lateral Sclerosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore our
Lateral Flow Assays Market - Smart Testing, Simplified: Lateral Flow Assays for …
Newark, New Castle, USA: The "Lateral Flow Assays Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors. Lateral Flow Assays Market: https://www.growthplusreports.com/report/lateral-flow-assays-market/8799 This latest report researches the industry structure,
Lateral Flow Assay Market
Worldwide Lateral Flow Assay Market Analysis to 2027 is a specialized and in-depth study of the Lateral Flow Assay industry with a focus on the global market trend. The report aims to provide an overview of global Lateral Flow Assay market with detailed market segmentation by product & services /application and geography. Get Sample PDF at https://www.theinsightpartners.com/sample/TIPRE00005544/?utm_source=OpenPR&utm_medium=Sumaiya Lateral flow tests, also known as lateral flow immunochromatographic assays. The lateral flow assay
Global Lateral Support Market Growth 2019-2024
LP INFORMATION offers a latest published report on Lateral Support Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. According to this study, over the next five years the Lateral Support market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular,